Encorafenib is a targeted therapy medication that works by blocking a specific protein called BRAF when it has a certain mutation (V600E). This medication helps slow down or stop the growth of cancer cells in colorectal cancer that has this specific genetic change.

Cetuximab is a type of medication called a monoclonal antibody. It works by targeting a protein called EGFR (epidermal growth factor receptor) that is found on the surface of cancer cells. By blocking this protein, cetuximab helps prevent cancer cells from growing and spreading. It is given through an intravenous infusion.

These medications are used together as a combination therapy for patients with colorectal cancer that has spread to other parts of the body (metastatic), specifically in cases where the cancer has a BRAF V600E mutation and the patient has previously responded to similar treatments.

Metastatic Colorectal Cancer (mCRC) with BRAF V600E mutation – A form of advanced colorectal cancer where cancer cells have spread beyond the original site to other parts of the body. This specific type is characterized by a mutation in the BRAF gene called V600E, which affects how cancer cells grow and divide. The disease begins in the colon or rectum and develops when healthy cells acquire this particular genetic mutation, leading to uncontrolled cell growth. As the disease progresses, cancer cells can break away from the primary tumor and travel through the blood or lymphatic system to form new tumors in other organs.